		Unaffected (N=9)	Affected (N=17)
Characteristic			
Median age - years		59	52
Female sex - no. (%)		2 (22)	8 (47)
Underlying diagnosis no. (%)			
	MDS/AML	2 (22)	6 (35)
	CML	1 (11)	0
	ALL	0	3 (18)
	CLL	0	1(6)
	NHL	3 (33)	1 (6)
	HL	0	2 (12)
	MGUS/MM	1(11)	2 (12)
	myelofibrosis	1 (11)	2 (12)
	sickle cell	1 (11)	0
Sex-matched transplant - no. (%)		4 (44)	5 (29)
HLA-matched transplant - no. (%)		8 (89)	9 (100)
Time since transplant - (years)		6	3.6
Time since sclerosis onset - (months)		N/A	12-18
	late no. (%)	N/A	8 (47)
History of acute skin GVHD - no. (%)		7 (78)	7 (41)
Biopsy site	arm	3 (33)	3 (18)
	abdomen	5 (56)	9 (53)
	back	1 (11)	2 (12)
	chest	0	1 (6)
	thigh	0	2 (12)
Clinical impression of skin	Stable	N/A	9 (53)
	Worsening	,	6 (35)
	Softening		2 (12)
Histology	Mild inflammation	N/A	12 (71)
	Moderate inflammation	N/A	5 (29)
	Mild necrotic ker.	N/A	5 (29)
	Moderate necrotic ker.	N/A	5 (29)
BSA		N/A	42%
Other GVHD organ involvement	lung	4 (44)	12 (71)
	liver	2 (22)	11 (65)
	ocular	5(56)	15 (88)
	oral	5 (56)	11 (65)
	genital	1 (11)	5 (29)
	joint	1 (11)	16 (94)
	gastrointestinal	2 (22)	4 (24)
Current systemic therapy	none	4 (44)	1 (6)
	prednisone	5 (56)	13 (76)
	ECP	2 (22)	8 (47)
	tacrolimus/cyclosporine	1 (11)	5 (29)
	sirolimus	0	6 (35)
	etanercept	0	1 (6)
	mycophenolate mofetil	0	6 (35)
	IVIG	0	1 (6)

Supplementary Table S1: Demographic and clinical characteristics summary. BSA, Body surface area; MDS, myelodysplastic syndrome; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; NHL, non-Hodgkin's lymphoma; HL, Hodgkin's lymphoma; MGUS, monoclonal gammopathy of undetermined significance; MM, multiple myeloma; ker, keratinocyte; ECP, extracorporeal photopheresis; IVIG, intravenous immunoglobulin.